These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. The tetrahydrobiopterin loading test in 36 patients with hyperphenylalaninaemia: evaluation of response and subsequent treatment. Bóveda MD; Couce ML; Castiñeiras DE; Cocho JA; Pérez B; Ugarte M; Fraga JM J Inherit Metab Dis; 2007 Oct; 30(5):812. PubMed ID: 17603758 [TBL] [Abstract][Full Text] [Related]
44. Impact of the phenylalanine hydroxylase gene on maternal phenylketonuria outcome. Güttler F; Azen C; Guldberg P; Romstad A; Hanley WB; Levy HL; Matalon R; Rouse BM; Trefz F; de la Cruz F; Koch R Pediatrics; 2003 Dec; 112(6 Pt 2):1530-3. PubMed ID: 14654659 [TBL] [Abstract][Full Text] [Related]
45. Two-year interim safety and efficacy of pegvaliase in Japanese adults with phenylketonuria. Ishige M; Ito T; Hamazaki T; Kuwahara M; Lee L; Shintaku H Mol Genet Metab; 2023 Nov; 140(3):107697. PubMed ID: 37717412 [TBL] [Abstract][Full Text] [Related]
46. Sapropterin dihydrochloride: a new drug and a new concept in the management of phenylketonuria. Trefz FK; Belanger-Quintana A Drugs Today (Barc); 2010 Aug; 46(8):589-600. PubMed ID: 20830319 [TBL] [Abstract][Full Text] [Related]
47. Fluctuations in phenylalanine concentrations in phenylketonuria: a review of possible relationships with outcomes. Cleary M; Trefz F; Muntau AC; Feillet F; van Spronsen FJ; Burlina A; Bélanger-Quintana A; Giżewska M; Gasteyger C; Bettiol E; Blau N; MacDonald A Mol Genet Metab; 2013 Dec; 110(4):418-23. PubMed ID: 24090706 [TBL] [Abstract][Full Text] [Related]
48. Phenylketonuria: a review of current and future treatments. Al Hafid N; Christodoulou J Transl Pediatr; 2015 Oct; 4(4):304-17. PubMed ID: 26835392 [TBL] [Abstract][Full Text] [Related]
49. Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria. Zori R; Thomas JA; Shur N; Rizzo WB; Decker C; Rosen O; Li M; Schweighardt B; Larimore K; Longo N Mol Genet Metab; 2018 Nov; 125(3):217-227. PubMed ID: 30146451 [TBL] [Abstract][Full Text] [Related]
50. Trends in enzyme therapy for phenylketonuria. Kim W; Erlandsen H; Surendran S; Stevens RC; Gamez A; Michols-Matalon K; Tyring SK; Matalon R Mol Ther; 2004 Aug; 10(2):220-4. PubMed ID: 15294168 [TBL] [Abstract][Full Text] [Related]
51. Clinical, genetic, and experimental research of hyperphenylalaninemia. Chen A; Pan Y; Chen J Front Genet; 2022; 13():1051153. PubMed ID: 36685931 [TBL] [Abstract][Full Text] [Related]
52. The Genetic Landscape and Epidemiology of Phenylketonuria. Hillert A; Anikster Y; Belanger-Quintana A; Burlina A; Burton BK; Carducci C; Chiesa AE; Christodoulou J; Đorđević M; Desviat LR; Eliyahu A; Evers RAF; Fajkusova L; Feillet F; Bonfim-Freitas PE; Giżewska M; Gundorova P; Karall D; Kneller K; Kutsev SI; Leuzzi V; Levy HL; Lichter-Konecki U; Muntau AC; Namour F; Oltarzewski M; Paras A; Perez B; Polak E; Polyakov AV; Porta F; Rohrbach M; Scholl-Bürgi S; Spécola N; Stojiljković M; Shen N; Santana-da Silva LC; Skouma A; van Spronsen F; Stoppioni V; Thöny B; Trefz FK; Vockley J; Yu Y; Zschocke J; Hoffmann GF; Garbade SF; Blau N Am J Hum Genet; 2020 Aug; 107(2):234-250. PubMed ID: 32668217 [TBL] [Abstract][Full Text] [Related]
53. Phenylketonuria. van Spronsen FJ; Blau N; Harding C; Burlina A; Longo N; Bosch AM Nat Rev Dis Primers; 2021 May; 7(1):36. PubMed ID: 34017006 [TBL] [Abstract][Full Text] [Related]
54. Functional Characterization of Novel Phenylalanine Hydroxylase p.Gln226Lys Mutation Revealed Its Non-responsiveness to Tetrahydrobiopterin Treatment in Hepatoma Cellular Model. Klaassen K; Djordjevic M; Skakic A; Desviat LR; Pavlovic S; Perez B; Stojiljkovic M Biochem Genet; 2018 Oct; 56(5):533-541. PubMed ID: 29654578 [TBL] [Abstract][Full Text] [Related]
55. The PAH gene, phenylketonuria, and a paradigm shift. Scriver CR Hum Mutat; 2007 Sep; 28(9):831-45. PubMed ID: 17443661 [TBL] [Abstract][Full Text] [Related]
56. Extended tetrahydrobiopterin loading test in the diagnosis of cofactor-responsive phenylketonuria: a pilot study. Fiege B; Bonafé L; Ballhausen D; Baumgartner M; Thöny B; Meili D; Fiori L; Giovannini M; Blau N Mol Genet Metab; 2005 Dec; 86 Suppl 1():S91-5. PubMed ID: 16290003 [TBL] [Abstract][Full Text] [Related]
57. Sapropterin: a review of its use in the treatment of primary hyperphenylalaninaemia. Sanford M; Keating GM Drugs; 2009; 69(4):461-76. PubMed ID: 19323589 [TBL] [Abstract][Full Text] [Related]
58. PTC923 (sepiapterin) lowers elevated blood phenylalanine in subjects with phenylketonuria: a phase 2 randomized, multi-center, three-period crossover, open-label, active controlled, all-comers study. Bratkovic D; Margvelashvili L; Tchan MC; Nisbet J; Smith N Metabolism; 2022 Mar; 128():155116. PubMed ID: 34973284 [TBL] [Abstract][Full Text] [Related]
59. Present and future of lipid nanoparticle-mRNA technology in phenylketonuria disease treatment. Diaz-Trelles R; Perez-Garcia CG Int Rev Cell Mol Biol; 2022; 372():159-174. PubMed ID: 36064263 [TBL] [Abstract][Full Text] [Related]